SRPT - Sarepta Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue5,4211,2539,757
Cost of Revenue130--
Gross Profit5,2911,2539,757
Operating Expenses
Research Development188,272146,39494,231
Selling General and Administrative83,74975,04349,315
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-266,730-220,184-133,789
Income from Continuing Operations
Total Other Income/Expenses Net---2,779
Earnings Before Interest and Taxes-267,265-220,030-135,789
Interest Expense---
Income Before Tax-267,265-220,030-135,789
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-267,265-220,030-135,789
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-267,265-220,030-135,789
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-267,265-220,030-135,789